TashkinDP. Measurement and significance of the bronchodilator response. In: JenneJW, MurphyS, eds. Drug therapy for asthma, research and clinical practice. New York: Marcel Dekker, 1987:535–613.
3.
JamesAL, ParePD, HoggJC. The mechanisms of airway narrowing in asthma. Am Rev Respir Dis1989;139:242–246.
4.
OrehekJ, NicoliMM, DelpierreS, BeaupreA.Influence of the previous deep inspiration on the spirometric measurement of provoked bronchoconstriction in asthma. Am Rev Respir Dis1981;123:269–272.
5.
BouhuysA, van de WoestijneKP. Mechanical consequences of airway smooth muscle relaxation. J Appl Physiol1971;30:670–676.
6.
WoolcockAJ, ReadJ.Lung volumes in exacerbations of asthma. Am J Med1966;41:259–273.
7.
JenneJW, TashkinDP. Bronchodilators as a bronchial challenge: a critical assessment. In: SpectorSL, ed. Provocative challenge procedures: bronchial, oral, nasal and exercise, Vol II. Boca Raton FL: CRC Press, 1983:19–73.
8.
AhrensRC, HarrisJB, MilavetzG, AnnisL, RiesR.Use of bronchial provocation with histamine to compare the pharmacodynamics of inhaled albuterol and metaproterenol in patients with asthma. J Allergy Clin Immunol1987;79:876–882.
9.
TorphyTJ, RinardGA, RietowMG, MayerSE. Functional antagonism in canine tracheal smooth muscle: inhibition by methacholine of the mechanical and biochemical responses to isoproterenol. J Pharmacol Exper Ther1983;227:694–699.
10.
TorphyTJ. Differential relaxant effects of isoproterenol on methacholine-versus-leukotriene D4-induced contraction in the guinea-pig trachea. Eur J Pharmacol1984;102:549–553.
11.
SpeizerFE, DollR, HeafP, StrangLB. Investigation into use of drugs preceding death from asthma. Br Med J1968;1:339–343.
NelsonHS, SpectorSL, WhitsettTL, GeorgeRB, DwekJH. The bronchodilator response to inhalation of increasing doses of aerosolized albuterol. J Allergy Clin Immunol1983;72:371–375.
14.
LewisRA. Inhalation drugs in asthma management: state of the art, factors affecting delivery, and clinical response to inhaled drugs. NER Allergy Proc1984;5(1):23–33.
15.
MestitzH, CoplandJM, McDonaldCF. Comparison of outpatient nebulized vs metered dose inhaler terbutaline in chronic airflow obstruction. Chest1989;96:1237–1240.
16.
PriorJG, NowellRV, CochraneGM. High-dose inhaled terbutaline in the management of chronic severe asthma: comparison of wet nebulisation and tube-spacer delivery. Thorax1982;37:300–303.
KraanJ, KoëterGH, MarkTW, SluiterHJ, de VriesK.Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J Allergy Clin Immunol1985;76:628–636.
19.
BentonG, ThomasRC, NickersonBG, McQuittyJC, OkikawaJ.Experience with a metered-dose inhaler with a spacer in the pediatric emergency department. AJDC1989;143:678–681.
20.
KellyHW, McWilliamsBC, KatzR, MurphyS.Safety of frequent high-dose nebulized terbutaline in children with acute severe asthma. Ann Allergy1990;64(Feb, Part II):229–233.
21.
RobertsonCF, SmithF, BeckR, LevisonH.Responses to frequent low doses of nebulized salbutamol in acute asthma. J Pediatr1985;106:672–674.
22.
WoodDW, DownsJJ, ScheinkopfH, LecksHI. Intravenous isoproterenol in the management of respiratory failure in childhood status asthmaticus. J Allergy Clin Immunol1972;50:75–81.
23.
CottonEK, ParryW.Treatment of status asthmaticus and respiratory failure. Pediatr Clin North Am1975;22:163–171.
24.
KurlandG, WilliamsJ, LewistonNJ. Fatal myocardial toxicity during continuous infusion intravenous isoproterenol therapy of asthma. J Allergy Clin Immunol1979;63:407–411.
25.
MatsonJR, LoughlinGM, StrunkRC. Myocardial ischemia complicating the use of isoproterenol in asthmatic children. J Pediatr1978;92:776–778.
26.
MaguireJF, GehaRS, UmetsuDT. Myocardial specific creatine phosphokinase isoenzyme elevation associated with intravenous isoproterenol therapy of childhood asthma (abstract). J Allergy Clin Immunol1986;77(1, Part 2):A109.
27.
LawfordP, JonesBJM, MilledgeJS. Comparison of intravenous and nebulised salbutamol in initial treatment of severe asthma. Br Med J1978;1:84.
28.
Van RenterghemD, LamontH, ElinckW, PauwelsR, Van Der StraetenM.Intravenous versus nebulized terbutaline in patients with acute severe asthma: a double-blind randomized study. Ann Allergy1987;59:313–316.
29.
ThiringerG, SvedmyrN.Comparison of infused and inhaled terbutaline in patients with asthma. Scand J Respir Dis1976;57:17–24.
30.
MolerFW, HurwitzME, CusterJR. Improvement in clinical asthma score and Paco2 in children with severe asthma treated with continuously nebulized terbutaline. J Allergy Clin Immunol1988;81:1101–1109.
31.
HarrisonBA, PierceRJ. Comparison of wet and dry aerosol salbutamol. Aust NZ J Med1983;13:29–33.
32.
JenkinsSC, HeatonRW, FultonTJ, MoxhamJ.Comparison of domiciliary nebulized salbutamol and salbutamol from a metered-dose inhaler in stable chronic airflow limitation. Chest1987;91:804–807.
33.
GrossNJ. Ipratropium bromide. N Engl J Med1988;319:486–494.
MarlinGE, BushDE, BerendN.Comparison of ipratropium bromide and fenoterol in asthma and chronic bronchitis. Br J Clin Pharmacol1978;6:547–549.
36.
RebuckAS, ChapmanKR, AbboudR, ParePD, KreismanH, WalkoneN, . Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room. Am J Med1987;82:59–64.
37.
WardMJ, FentemPH, Roderick SmithWH, DaviesD.Ipratropium bromide in acute asthma. Br Med J1981;282:598–600.
38.
BryantDH. Nebulized ipratropium bromide in the treatment of acute asthma. Chest1985;88:24–29.
39.
LeahyRC, GommSA, AllenSC. Comparison of nebulized salbutamol with nebulized ipratropium bromide in acute asthma. Br J Dis Chest1983;77:159–163.
40.
IngramRHJr, WellmanJJ, McFaddenERJr, MeadJ.Relative contributions of large and small airways to flow limitation in normal subjects before and after atropine and isoproterenol. J Clin Invest1977;59:696–703.
41.
KarpelJP, AppelD, BreidbartD, FuscoMJ. A comparison of atropine sulfate and metaproterenol sulfate in the emergency treatment of asthma. Am Rev Respir Dis1986;133:727–729.
42.
HigginsRM, StradlingJR, LaneDJ. Should ipratropium bromide be added to beta-agonists in treatment of acute severe asthma?Chest1988;94:718–722.
43.
EastonPA, JadueC, DhingraS, AnthonisenNR. A comparison of the bronchodilating effects of a beta-2 adrenergic agent (albuterol) and an anticholinergic agent (ipratropium bromide) given by aerosol alone or in sequence. N Engl J Med1986;315:735–739.
44.
FraserI, DuVallA, DolovichM, NewhouseMT. Therapeutic aerosol delivery in ventilator systems (abstract). Am Rev Respir Dis1981;123(4, Part 2):107.
45.
MacIntyreNR, SilverRM, MillerCW, SchulerF, ColemanRE. Aerosolized delivery in intubated, mechanically ventilated patients. Crit Care Med1985;13:81–84.
46.
CroganSJ, BishopMJ. Delivery efficiency of metered dose aerosols given via endotracheal tube. Anesthesiology1989;70:1008–1010.
47.
FullerHD, DolovichMB, PosmituckG, Wong PackW, NewhouseMT. Pressurized aerosol versus jet aerosol delivery to mechanically ventilated patients. Am Rev Respir Dis1990;141:440–444.
48.
LarsonRP, BishopMJ, BuschmanDL. Metered dose inhaler actuator adapters: a comparison of particle size and drug delivery through an endotracheal tube (abstract). Respir Care1989;34:1029.